Related Experiment Video

Updated: Aug 21, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Novel antiangiogenic therapies for renal cell cancer

Michael S Gordon1

  • 1Arizona Cancer Center-Greater Phoenix Area, University of Arizona College of Medicine, Scottsdale, Arizona 85258, USA. msgordon@u.arizona.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 28, 2004
PubMed

Insights

Antiangiogenic therapies targeting vascular endothelial growth factor (VEGF) show promise for metastatic renal cell cancer. Further studies are needed to assess the value of VEGF inhibitors and combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell cancer lacks highly effective therapies for most patients.
  • Clear cell carcinomas are linked to von Hippel-Lindau gene mutations, increasing vascular endothelial growth factor (VEGF) expression.
  • Angiogenesis is a key pathophysiologic mechanism in renal cell carcinoma development.

Purpose of the Study:

  • To explore the potential of antiangiogenic therapy for renal cell cancer.
  • To review various antiangiogenic agents beyond VEGF inhibitors.
  • To discuss the role of combination therapies in treating renal cell cancer.

Main Methods:

  • Review of existing studies on antiangiogenic agents for renal cell cancer.
  • Analysis of agents including VEGF inhibitors, thalidomide, low-dose interferon, and thrombospondin-1 mimetics.
  • Consideration of combination therapy strategies.

Main Results:

  • Antiangiogenic agents have shown objective responses or disease stabilization in some patients.
  • VEGF inhibitors represent a promising therapeutic avenue.
  • Thalidomide, interferon, and thrombospondin-1 mimetics are under investigation.

Conclusions:

  • Antiangiogenic therapy is an intriguing concept for renal cell cancer treatment.
  • Ongoing prospective studies are crucial to determine the true value of these agents.
  • Exploring combinations of antiangiogenic agents with other therapies warrants investigation.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...